David Trainer On Why Valeant Phamaceuticals Is In The Danger Zone
CEO David Trainer sat down with Chuck Jaffe of Money Life and MarketWatch.com to talk about our Danger Zone pick this past week: Danger Zone: Valeant Pharmaceuticals (VRX).
Kyle Guske II, Senior Investment Analyst, MBA














